ovosiston profile

Ovosiston: combination of mestranol & chlormadinone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	66465
MeSH ID	M0043520

Synonym
8065-91-6
sequens
femigen
s-3850 ,
estirona
ak 103
aconcen
ovosiston
lutestral [french]
sequence-ovosiston
gestranol
[(8r,9s,10r,13s,14s,17r)-17-acetyl-6-chloro-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-3-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-ol

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	18 (90.00)	18.7374
1990's	2 (10.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	7 (31.82%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (68.18%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	1.96	1	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
norethindrone acetate norethisterone acetate : A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.	1.97	1	3-oxo-Delta(4) steroid; acetate ester; terminal acetylenic compound	progestin; synthetic oral contraceptive
lynestrenol Lynestrenol: A synthetic progestational hormone used often in mixtures with estrogens as an oral contraceptive (CONTRACEPTIVES, ORAL).	1.96	1	steroid
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	3.35	7	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
norethindrone Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.	3.46	8	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	progestin; synthetic oral contraceptive
mestranol [no description available]	4.31	20	17beta-hydroxy steroid; aromatic ether; terminal acetylenic compound	prodrug; xenoestrogen
chlormadinone acetate Chlormadinone Acetate: An orally active synthetic progestational hormone used often in combinations as an oral contraceptive (CONTRACEPTIVES, ORAL).	4.31	20	corticosteroid hormone
chromium Chromium: A trace element that plays a role in glucose metabolism. It has the atomic symbol Cr, atomic number 24, and atomic weight 52. According to the Fourth Annual Report on Carcinogens (NTP85-002,1985), chromium and some of its compounds have been listed as known carcinogens.. chromium ion : An chromium atom having a net electric charge.. chromium atom : A chromium group element atom that has atomic number 24.	2	1	chromium group element atom; metal allergen	micronutrient
ethinyl estradiol-norgestrel combination Ethinyl Estradiol-Norgestrel Combination: ETHINYL ESTRADIOL and NORGESTREL given in fixed proportions.	3.06	5
noracycline Noracycline: contains lynestrenol & mestranol	1.96	1
diethylstilbestrol Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.	1.95	1	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen
cystine [no description available]	1.96	1
bilirubin [no description available]	1.95	1	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
non-ovlon Non-Ovlon: inhibits ovulation; contains above two cpds	3.21	6
deposiston Deposiston: depot estrogen containing 17 alpha-ethinyl-3-isopropylsulfonyloxy-estradiol + norethisterone	2.87	4
norgestrel Norgestrel: A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis.	3.06	5

Condition	Relationship Strength	Studies
Cystine Diathesis [description not available]	1.96	1
Hepatocellular Carcinoma [description not available]	2.36	2
Hypersensitivity, Type III [description not available]	1.96	1
Kidney Stones [description not available]	1.96	1
Cancer of Liver [description not available]	2.36	2
Embolism, Pulmonary [description not available]	1.96	1
Phlegmasia Alba Dolens Inflammation that is characterized by swollen, pale, and painful limb. It is usually caused by DEEP VEIN THROMBOSIS in a FEMORAL VEIN, following PARTURITION or an illness. This condition is also called milk leg or white leg.	1.96	1
Antithrombin 3 Deficiency [description not available]	1.96	1
Cystinosis A metabolic disease characterized by the defective transport of CYSTINE across the lysosomal membrane due to mutation of a membrane protein cystinosin. This results in cystine accumulation and crystallization in the cells causing widespread tissue damage. In the KIDNEY, nephropathic cystinosis is a common cause of RENAL FANCONI SYNDROME.	1.96	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.36	2
Kidney Calculi Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.	1.96	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.36	2
Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.	1.96	1
Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.	1.96	1
Thrombophlebitis Inflammation of a vein associated with a blood clot (THROMBUS).	1.96	1
Antithrombin III Deficiency An absence or reduced level of Antithrombin III leading to an increased risk for thrombosis.	1.96	1
Fetal Death Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.	1.96	1
Fetal Growth Restriction [description not available]	1.96	1
Abnormalities, Drug-Induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.	1.96	1
Fetal Growth Retardation Failure of a FETUS to attain expected GROWTH.	1.96	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.87	4
Bleeding [description not available]	1.96	1
Hemoperitoneum Accumulations of blood in the PERITONEAL CAVITY due to internal HEMORRHAGE.	1.96	1
Hemorrhage Bleeding or escape of blood from a vessel.	1.96	1
Blood Pressure, High [description not available]	1.96	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	1.96	1
Abdominal Migraine [description not available]	1.96	1
Cephalgia, Vascular [description not available]	1.96	1
Migraine Disorders A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)	1.96	1
Recrudescence [description not available]	1.95	1
Icterus [description not available]	1.95	1
Hypomenorrhea [description not available]	1.95	1
Complications, Pregnancy [description not available]	1.95	1
Jaundice A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.	1.95	1
Acute Liver Injury, Drug-Induced [description not available]	1.96	1
Hemorrhagic Thrombocythemia [description not available]	1.96	1
Thrombocythemia, Essential A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.	1.96	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	1.96	1
Complication, Postoperative [description not available]	1.97	1
Androgen Insensitivity Syndrome [description not available]	1.97	1
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	1.97	1
Cardiovascular Stroke [description not available]	1.97	1
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	1.97	1
Bile Duct Obstruction, Intrahepatic [description not available]	1.96	1
Viral Hepatitis, Human [description not available]	1.96	1
Cholestasis, Intrahepatic Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).	1.96	1
Hepatitis, Viral, Human INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).	1.96	1

ovosiston

Description

Cross-References

Synonyms (12)

Research

Studies (20)

Market Indicators

Research Demand Index: 25.81

Study Types

ovosiston

Description

Cross-References

Synonyms (12)

Research

Studies (20)

Market Indicators

Research Demand Index: 25.81

Study Types

Related Drugs (16)

Related Conditions (47)